Company intelligence / Profile preview

Bio X Cell

Lebanon, New Hampshire, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Bio X Cell supplies ultra-pure monoclonal antibodies formulated for in vivo pre-clinical research, focusing on immunity modulation, checkpoint blockade, and cell biology. Their products are widely cited in academic research and used in studies but do not themselves progress as drug candidates to clinical stages.

Therapeutic areas: OncologyNeurologyImmunology
Modalities: Monoclonal antibodyRecombinant protein
Industry: Chemicals & Materials

Beyond the preview

Go deeper on Bio X Cell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bio X Cell.

Explore the full profile